KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $2.3 million.

  • Esperion Therapeutics' Share-based Compensation fell 22.27% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 15.03%. This contributed to the annual value of $12.0 million for FY2024, which is 0.29% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Share-based Compensation is $2.3 million, which was down 11.99% from $2.7 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Share-based Compensation high stood at $8.6 million for Q2 2021, and its period low was $2.3 million during Q3 2025.
  • Its 3-year average for Share-based Compensation is $2.9 million, with a median of $2.9 million in 2023.
  • Per our database at Business Quant, Esperion Therapeutics' Share-based Compensation increased by 16.08% in 2021 and then plummeted by 58.91% in 2022.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Share-based Compensation stood at $4.5 million in 2021, then dropped by 16.96% to $3.7 million in 2022, then fell by 21.40% to $2.9 million in 2023, then declined by 3.94% to $2.8 million in 2024, then decreased by 22.27% to $2.3 million in 2025.
  • Its Share-based Compensation stands at $2.3 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.5 million for Q1 2025.